À l’heure où des techniques innovantes de dépistage sur le lieu de soins (POC) sont mises sur le marché, le présent rapport soumet à l’attention des gouvernements un examen des principaux aspects relatifs à leur introduction et à leur extension au sein des programmes publics nationaux. L...’élargissement de la portée de cette stratégie aux réseaux nationaux de dépistage des laboratoires conventionnels contribuerait à la réalisation des objectifs d’accélération de la riposte visant à mettre fin à l’épidémie de sida d’ici à 2030.
Le dépistage sur le lieu de soins, lorsqu’il est stratégiquement mis en place et intégré dans les réseaux nationaux de dépistage, peut contribuer à promouvoir des changements et à améliorer la prestation des services cliniques et de dépistage. Le présent document s’inspire de l’expérience acquise en matière d’introduction, par le biais de financements catalysateurs, de techniques de dépistage sur le lieu de soin dans les programmes et les marchés de nombreux pays d’Afrique subsaharienne pour défendre ce point de vue.
more
This concept note describes the methods used to assess the prevalence of any HIVDR and HIVDR by PMTCT exposure among children less than 18 months of age using remnant dried blood spot specimens from early infant diagnosis over a 12-month period
Conflict and Health, vol. 9 Supplment 1. Free download of all articles at: http://www.conflictandhealth.com/supplements/9/S1
The IAWG has undertaken an updated review to identify services, quantify progress, document gaps and determine future directions for programs, advocacy and funding prioriti...es. The 2014 review clearly highlights that humanitarian and development actors must identify and develop effective strategies to meaningfully engage affected communities to icrease use of reproductive health services, meet their reproductive health needs, and augment participation in the programs that affect their lives
more
This inventory has been compiled by WHO/Europe to help facilitate monitoring and reporting of national policies for the prevention of violence and injuries, in close collaboration with national focal persons officially nominated by ministries of health and with support from the European Commission (...EC).
The documents in the inventory reflect policy initiatives undertaken at national level in countries across the Region by different sectors involved in the prevention of violence and injuries, such as health, justice, interior, social affairs, transport.
Information can be viewed and searched on a country basis or in a summary table, listing all countries, by clicking one of the tabs above. This facilitates the sharing of information by Member States and comparisons across the WHO European Region.
This inventory is one of the products of a joint WHO/EC project on preventing injury and promoting safety in Europe.
More information about prevention of violence and injuries can be found in the WHO/Europe website on violence and injury prevention.
more
It is essential that all people, including people living with HIV, are able to access health services and ongoing treatment. If people living with HIV who are on ART stop abruptly because they cannot access new supplies they could rapidly become unwell, drug resistance may build and the chances of o...nward transmission of the virus would increase.
more
Version: 14 March 2019; A one-page reference guide to all the anti-HIV drugs licensed for use in the European Union, with information on formulation, dosing, key side-effects and food restrictions.
The previous edition of the drugs chart is also available to download in Russian.
Translated and adapted from the original English Antiretroviral drugs chart by the East Europe and Central Asia Union of People Living with HIV (ECUO). This resource shows drugs currently available in the Eastern Europe and Central Asia area.
Last update Oct. 2018
The Panel recommendations on initial combination regimens for the antiretroviral therapy (ART)-naive, HIV-infected patients.
This document describes the key areas that national governments should consider for the introduction and scale-up of point-of-care (POC) diagnostics within national programmes, as new innovative POC technologies are being introduced into the market. The next steps taken to include these new innovati...ons within the broader context of national diagnostic networks of conventional laboratories could influence the achievement of the 2030 Fast Track targets for ending the AIDS epidemic.
POC diagnostics, when strategically introduced and integrated into national diagnostic networks, may help catalyse changes that improve the way diagnostics and clinical services are delivered. This document distils this understanding based on programmatic and market experiences of introducing POC diagnostics through catalytic investments in POC HIV technologies across numerous countries in sub-Saharan Africa.
more
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more
This publication is an updated version of the Management of Tuberculosis and HIV Coinfection clinical protocol released in 2007 by the WHO Regional Office for Europe. It is intended for all health care workers involved in preventing, diagnosing, treating and caring for people living with TB and HIV ...in the specific settings of the WHO European Region.
more
The following information provides guidance to health care providers attending to the medical needs of HIV-infected adults (including pregnant women) or children displaced from disaster areas who have not yet secured HIV care in the areas where they have relocated.
(*)
- HHS Panel on Antiretrov...iral Guidelines for Adults and Adolescents
- HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission
- HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children
- HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults & Adolescents
- HHS Panel on Guidelines for the Prevention and Treatment of Opportunistic Infection in HIV-Infected Children
more
We have created a special Toolbox on HIV, please click here to see all guidelines, manuals, reports & studies
Co-trimoxazole is a fixed-dose combination of two antimicrobial drugs (sulfamethoxazole and trimethoprim) that covers a variety of bacterial, fungal and protozoan infections. Co-trimoxazole preventive therapy is a feasible, well tolerated and inexpensive intervention for people living with HIV to re...duce HIV-related morbidity and mortality. Further, co-trimoxazole is an off-patent drug and widely available in resource-limited settings.
more
Cryptococcal disease, particularly cryptococcal meningitis is a significant cause of morbidity and mortality among people living with HIV with advanced HIV disease. It is estimated that it is responsible for nearly 19% of AIDS-related mortality, second only to tuberculosis. Rapid screening, diagnosi...s and linking to appropriate treatment are critical actions national programs must take to reduce the burden of disease.
WHO in 2022 introduced updated guidelines for diagnosing, preventing, and managing cryptococcal disease among adults, adolescents and children living with HIV. This policy brief provides a summary of the key recommendations, clinical considerations, and also stresses the importance of ensuring access to life-saving antifungals. There is an urgent need for countries to scale-up management for not just cryptococcal meningitis, but address cryptococcal disease in the context of a package of care for advanced HIV disease as recommended by WHO.
more